CA2681639A1 - Compounds and methods for treatment of disorders associated with er stress - Google Patents

Compounds and methods for treatment of disorders associated with er stress Download PDF

Info

Publication number
CA2681639A1
CA2681639A1 CA002681639A CA2681639A CA2681639A1 CA 2681639 A1 CA2681639 A1 CA 2681639A1 CA 002681639 A CA002681639 A CA 002681639A CA 2681639 A CA2681639 A CA 2681639A CA 2681639 A1 CA2681639 A1 CA 2681639A1
Authority
CA
Canada
Prior art keywords
independently
lower alkyl
substituted
occurrence
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002681639A
Other languages
English (en)
French (fr)
Inventor
Teoman Uysal
Nicholas D.P. Cosford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYNDEXA PHARMACEUTICALS CORP
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2681639A1 publication Critical patent/CA2681639A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002681639A 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress Abandoned CA2681639A1 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US78518206P 2006-03-22 2006-03-22
US78533506P 2006-03-22 2006-03-22
US78503406P 2006-03-22 2006-03-22
US78500706P 2006-03-22 2006-03-22
US78533806P 2006-03-22 2006-03-22
US78523506P 2006-03-22 2006-03-22
US78503506P 2006-03-22 2006-03-22
US78518506P 2006-03-22 2006-03-22
US78532806P 2006-03-22 2006-03-22
US78515406P 2006-03-22 2006-03-22
US60/785,335 2006-03-22
US60/785,235 2006-03-22
US60/785,328 2006-03-22
US60/785,034 2006-03-22
US60/785,007 2006-03-22
US60/785,035 2006-03-22
US60/785,154 2006-03-22
US60/785,182 2006-03-22
US60/785,185 2006-03-22
US60/785,338 2006-03-22
PCT/US2007/007228 WO2007111994A2 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress

Publications (1)

Publication Number Publication Date
CA2681639A1 true CA2681639A1 (en) 2007-10-04

Family

ID=38541676

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002681639A Abandoned CA2681639A1 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress

Country Status (6)

Country Link
US (1) US20090131384A1 (enExample)
EP (1) EP2001897A2 (enExample)
JP (1) JP2009530399A (enExample)
AU (1) AU2007230991A1 (enExample)
CA (1) CA2681639A1 (enExample)
WO (1) WO2007111994A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518278B1 (pt) 2004-10-26 2018-04-24 Dolby Laboratories Licensing Corporation Método e aparelho para controlar uma característica de sonoridade particular de um sinal de áudio
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2367839A4 (en) * 2008-11-03 2012-07-04 Univ Tufts METHOD AND COMPOSITIONS FOR INHIBITING CLOSTRIDIUM DIFFICILE SPORTS NUTRITION AND GROWTH
EP2255813A1 (en) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
PL2519100T3 (pl) 2009-12-29 2017-09-29 Mapi Pharma Limited Związki pośrednie i sposoby wytwarzania tapentadolu i pokrewnych związków
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
TWI499412B (zh) 2010-06-16 2015-09-11 亞德生化公司 苯基硫乙酸酯組合物及其使用方法
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2704233T3 (es) 2011-11-03 2019-03-15 Ardea Biosciences Inc Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo
EP2844257A4 (en) 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN111529535A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
ES2736599T3 (es) 2013-03-14 2020-01-03 Univ Macau Nuevos compuestos naturales antineurodegenerativos aislados a partir de Alpiniae oxyphyllae fructus y síntesis total de los mismos
PL3925607T5 (pl) 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
BR112017009657A2 (pt) * 2014-11-06 2018-01-23 Enanta Pharmaceuticals, Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
RU2017121457A (ru) 2014-11-26 2018-12-26 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
AU2016219266A1 (en) 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
RU2712099C2 (ru) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
DE102017005884A1 (de) * 2016-07-07 2018-01-11 Merck Patent Gmbh Elektronisches Schaltelement
AU2017368069B2 (en) 2016-11-29 2021-07-08 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
MX388300B (es) 2017-04-07 2025-03-19 Enanta Pharm Inc Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
DE102018004733B4 (de) * 2018-06-14 2026-06-11 Merck Patent Gmbh Verfahren zur Herstellung eines elektronischen Bauteils enthaltend eine selbstorganisierte Monolage
CN116925168A (zh) 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
JP2024529444A (ja) * 2021-07-26 2024-08-06 シャペロン インク． ＴＮＦ－α生成及び炎症複合体活性抑制新規化合物及びその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1152801B (it) * 1982-08-17 1987-01-14 Proter Spa Composti steroidei ad attivita' coleretica, processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo
JPS60161996A (ja) * 1984-02-01 1985-08-23 Eisai Co Ltd ケノデオキシコ−ル酸またはウルソデオキシコ−ル酸誘導体およびその製造法ならびにそれを含有する医薬
JP2616845B2 (ja) * 1991-02-21 1997-06-04 清水化学株式会社 システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
JPH0959162A (ja) * 1995-08-28 1997-03-04 Makoto Takahashi 胆石溶解剤
WO2001076531A2 (en) * 2000-04-07 2001-10-18 University Of Maryland, Baltimore Bile acid containing prodrugs with enhanced bioavailability
AU2002230398A1 (en) * 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs

Also Published As

Publication number Publication date
JP2009530399A (ja) 2009-08-27
US20090131384A1 (en) 2009-05-21
AU2007230991A1 (en) 2007-10-04
WO2007111994A2 (en) 2007-10-04
EP2001897A2 (en) 2008-12-17
WO2007111994A3 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
US20090131384A1 (en) Compounds and methods for treatment of disorders associated with er stress
JP6101675B2 (ja) 代謝病の治療用の化合物
AU2007319848B2 (en) Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners
TWI351395B (en) Large-scale synthesis of selective androgen recept
EP2125697B1 (en) Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates
CN103096895B (zh) 烟酸模拟物及其使用的方法
JP7053478B2 (ja) Ｆｘｒアゴニストを使用するための方法
CA2955987A1 (en) Synthetic triterpenoids and methods of use in the treatment of disease
TW200422041A (en) Method of treatment for sexual dysfunction
JP7383124B2 (ja) リモノイド化合物およびｄｐｐ－４阻害剤を含有する組合せ製品
TW201336831A (zh) 作為鈣感測受體調節劑之取代二氫苯並哌喃化合物
AU2013290100A1 (en) Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2022544299A (ja) リモノイド化合物およびチアゾリジンジオン化合物を含有する組合せ製品
TW202515549A (zh) 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250313522A1 (en) Phenoxy carboxylic acid compounds and medical uses thereof
JP2009519946A (ja) タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法
AU2013257710B2 (en) Compositions and methods for the treatment of neurological disorders
CN102659570B (zh) 二氟非诺贝特酸及其在药学上可接受的盐，以及它们的制备方法和应用
JP2024041865A (ja) パ－キンソン病治療用の新規高透過薬物及びその組成物
WO2023160702A1 (zh) 氨基脂质化合物、其制备方法、组合物和应用
WO2015120610A1 (en) Gpr142 agonist compound
CN102432607A (zh) 一种吡嗪异喹啉衍生物在制备治疗血吸虫药物中的应用
US20130317034A1 (en) Combination therapy for treating diabetes
WO2013070911A1 (en) Compounds and methods for treating cystic fibrosis
US20230331690A1 (en) Thc derivatives, oral dosage forms comprising same, uses thereof for treating diseases and disorders and synthesis thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130322